One of the highlights of the Clínic-IDIBAPS participation in the European Society for Medical Oncology (ESMO) 2024 Congress was Dr. Josep M. Llovet’s1
A study by the Clínic-IDIBAPS shows that silencing this gene reduces the growth of liver cancer in mice. The research, using different animal models,1
Dr. Llovet (Clínic-IDIBAPS) and Dr. Bustelo (CSIC-University of Salamanca) coordinate the ASPIRE-AECC project, which includes 15 hospitals to conduct1
The project, funded by the European Union and endowed with a budget of 24.8 million euros, aims to identify a large set of biomarkers that allow live1
Researchers from the Hospital Clínic-IDIBAPS have published a review in Nature Reviews Clinical Oncology about the adjuvant and neoadjuvant treatment1
Endowed with €12 million, the project is coordinated by Prof. Josep M. Llovet, the head of the IDIBAPS group Translational Research in Hepatic Oncolo1
The IDIBAPS Board of Trustees has approved the creation of a new research group. The decision results from a scientific evaluation by the ad hoc comm1
IDIBAPS researchers have reviewed the role of fibroblasts, a type of cell found in the liver, in the progression of liver cancer, both hepatocellular1
Researchers from the Hospital Clínic-IDIBAPS have participated in the preparation of the new guidelines on intrahepatic cholangiocarcinoma, the secon1
The IDIBAPS researcher Josep M. Llovet has participated in the new American AASLD guidelines for the treatment of hepatocellular carcinoma, the most1
